Urine examination of the donor did not reveal hematuria. The patient underwent his renal transplant with mother as a donor on January 8, 2015 at our center in Chennai. He was inducted with single-dose thymoglobulin 75 mg following which, he was initiated on triple immunosuppressive therapy, which included prednisolone 25 mg once a day, tacrolimus 2.5 mg in the morning and 3 mg in the night, and mycophenolate mofetil 750 mg twice a day. On postoperative day 0, his creatinine was 4.93 mg/dl and urea was 38 mg/dl. On the 2 nd postoperative day, creatinine became 0.86 mg/dl and urea was 21 mg/dl. On the 5 th postoperative day, he developed purpuric rashes without any abdominal pain or arthralgia. His platelet count was 200,000/mm 3 , total white blood cell count was 5900 with 58% of neutrophils, and hemoglobin was 8.1 g/dl. Peripheral smear was not showing any features of hemolysis. His renal function was normal with blood urea of 18 mg/dl and serum creatinine of 0.9 mg/dl. Optic fundus was unremarkable. On the 6 th postoperative day, urine examination was done and it revealed hematuria (red blood cell >50/high-power field [hpf]), leukocytes (15-20/hpf), with granular casts and trace albumin. Urine culture was sterile. Urine protein creatinine ratio was 2.61. Ultrasound of the graft showed normal allograft with no perinephric collection. Renal biopsy was done, and it revealed mild mesangial expansion with normal interstitium and tubules. Immunofluorescence [ Figure 1 ] showed IgA2+ and IgA3+ positive and C 4 D negative. All the features were suggestive of recurrent IgAN in renal allograft. His renal function was monitored serially, and it was normal [ Figure 2 ]. Serum IgA level was within normal limits, i.e., 2.3 g/l (0.7-4 g/l). Triple immunosuppressants were continued. He was followed up regularly. Currently, his renal allograft is functioning well with serum creatinine of 1.5mg/dL, 5-6 RBC in urine, no Proteinuria and no evidence of skin lesions.
discussion
Initially, IgAN was considered as a benign disease, but in Indians, it is a malignant disease due to genetic and environmental factors. IgAN patients who had undergone renal transplant face the risk of recurrence in their kidney graft. [4] Recurrence of the original disease is now the third most frequent cause of allograft loss at 10 years after transplantation in patients with underlying GN. Clinical features of recurrent IgAN are persistent microhematuria as in our patient and proteinuria exceeding 0.5 g/day but usually remains below the nephrotic range. Gross hematuria associated with upper respiratory tract infections is seen less frequently. [5] Recurrence of IgAN should be proved histologically. Recurrent IgAN will show mesangial expansion with IgA deposits in the biopsy as in our patient. Very rarely, recurrent IgAN will present as crescentic GN with rapidly progressive renal failure. Observational studies of patients transplanted due to IgAN have shown that IgA recurs in up to 60% of patient's grafts as in our patient. [6, 7] Twenty-nine percent of patients with recurrent IgAN had graft dysfunction. Graft dysfunction was more in patients with a transplant from a live-related donor. The only established predictor of graft loss is the time elapsed since renal transplantation as rate of recurrence increases as time from transplant lengthens. [6] However, this is not the case with our patient.
Our patient had recurrence of IgA vasculitis as shown by purpuric rashes, active urinary sediments, and mild proteinuria. The diagnosis of IgAN recurrence requires histological evidence of IgA in the transplant kidney in a patient with biopsy-proven IgA disease in their native kidneys. As of now, no treatment has been shown to halt, or even slow down, the development of clinical IgAN recurrence. Biopsy of our patient taken on the 6 th postoperative day was showing mesangial expansion, and immunofluorescence revealed IgA3+.This patient is a rare case of recurrence of IgAN within 6 days of allografting with long-term good outcome over 2 years of follow-up.
conclusion
We are presenting an interesting case in which IgAN recurred on the 6 th postoperative day in a renal allograft recipient with adequate allograft function.
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